Consider a long position in Eli Lilly (LLY), which is dominating the GLP-1 drug market and aggressively reinvesting profits into R&D and manufacturing to secure future growth. For broader exposure to this theme, also consider its main competitor, Novo Nordisk (NVO), as the market for these drugs expands beyond weight loss into mental health and addiction. The struggling biotech sector has created a buyer's market, making discounted small-cap companies with promising science potential acquisition targets for large pharma. Conversely, be cautious of major Pharmacy Benefit Managers (PBMs) within companies like CVS Health and Cigna, as they face significant business model and regulatory headwinds. An oral pill version of LLY's GLP-1 drug expected next year could serve as a major catalyst by expanding market access.

Eli Lilly and Company (LLY)

• The company's stock has seen massive growth, with its market capitalization increasing by 860% and stock price up over 1,000% since the current CEO, Dave Ricks, took over.
• Its GLP-1 drug, Mounjaro (terepatide), has become the best-selling drug in the world, generating $8.1 billion in revenue in Q2 alone, with an 80% growth rate.
• Eli Lilly is heavily reinvesting its profits back into the business with a clear capital allocation strategy:
  • 1. Research & Development (R&D): The company is spending 25% of its sales on R&D, amounting to $14.2 billion this year. This is a massive commitment to finding the next breakthrough drug.
  • 2. Supply Chain Expansion: To meet overwhelming demand, Lilly is building six new manufacturing plants in the U.S. and plans to announce four more soon. This is a capital-intensive move to secure its market position.
  • 3. Acquisitions: The company is actively buying smaller biotech companies to bring in external innovation, making a deal roughly "every two weeks." The recent acquisition of gene therapy company Verve Therapeutics is an example.

Takeaways

• Bullish Sentiment: The discussion around Eli Lilly is overwhelmingly positive, highlighting its dominant market position, explosive growth, and robust pipeline.
• Future Growth Drivers:
  • An oral (pill) version of their GLP-1 drug is expected next year, which could significantly expand its accessibility and market.
  • The company is exploring new uses for its drugs beyond weight loss, including mental health (bipolar, depression) and addiction, with a new drug specifically for these uses potentially coming in 3-4 years.
• Pricing Strategy: The CEO is committed to lowering the price of GLP-1 drugs over time, with an expected 5-10% annual price decrease. While this may seem like a negative, the goal is to secure wider insurance reimbursement and increase volume, which could be a net positive for long-term revenue.
• Risks to Watch:
  • Patent Expiration: Like all pharmaceutical companies, Lilly faces a "patent cliff." The patent for Mounjaro will expire in the 2030s, at which point revenue from that specific drug will drop significantly. The company's heavy R&D spending is its strategy to mitigate this long-term risk.
  • Competition: A significant "gray market" for counterfeit drugs, particularly from China, exists due to high demand and cost. Furthermore, Chinese state-subsidized firms are actively trying to create similar drugs that work around Lilly's patents.

GLP-1 Drugs (Investment Theme)

• This class of drugs, originally for diabetes, has created a "gold rush" in the weight-loss market. An estimated 20 million people are currently taking prescription GLP-1s globally.
• The discussion highlights that the current uses are just the beginning. The drugs are showing broad, positive "pleiotropic effects" on the body.
• Future potential applications being studied or observed include:
  • Addiction: Anecdotal and clinical evidence shows reductions in smoking, gambling, and even online shopping.
  • Mental Health: Studies are being launched for bipolar disorder and major depressive disorder.
  • Dementia: Competitor Novo Nordisk (NVO) has a study on dementia risk reading out soon. While the CEO is cautious, he expects the results to be "in the right direction."
  • Longevity: The CEO speculates that in the future, taking low doses of these drugs could become common for people over 60 to promote healthier aging.

Takeaways

• Expanding Total Addressable Market (TAM): The investment thesis for GLP-1s is expanding far beyond just diabetes and obesity. If these drugs prove effective for mental health, addiction, or dementia, the market size could be multiples of what it is today.
• Key Players: The dominant companies in this space are Eli Lilly (LLY) and its competitor Novo Nordisk (NVO). Investors interested in this theme should focus on these two leaders.
• Long-Term Trend: The conversation frames GLP-1s not as a fad, but as a foundational medical technology that will evolve and find new uses over the next decade, similar to how SSRIs became widespread for mental health.

Biotech Sector

• The current funding environment for smaller biotech companies is described as a "dumpster fire."
• Venture capital funding for biotech has cratered from a peak of $20 billion per year to around $5 billion.
• Reasons for the downturn include:
  • Competition for investment from hotter sectors like AI.
  • A flooded IPO market where many investors are "deeply underwater," with half of publicly traded biotechs trading at or below their cash value.
  • Pressure from Chinese firms creating derivative drugs, which hurts valuations.

Takeaways

• Bearish Short-Term: The sector is facing significant headwinds, making it a difficult environment for generalist investors. Many smaller, publicly traded biotech companies may struggle to survive or raise capital.
• Acquisition Opportunities: The downturn has created a buyer's market for large pharmaceutical companies like Eli Lilly. This presents a potential investment strategy: identifying well-run, small-cap biotech companies with promising science that are trading at a discount, as they may become acquisition targets. Verve Therapeutics (VERV), recently acquired by Lilly, is a prime example of this dynamic.

Pharmacy Benefit Managers (PBMs)

• PBMs are the intermediaries in the drug supply chain that negotiate prices and manage pharmacy claims.
• The CEO of Eli Lilly expressed a negative view on the industry, stating we are likely at the "end of that S cycle" for PBMs and that they have become self-serving, which is why "everybody hates them."
• The rise of smaller, more transparent PBMs is noted as a potential disruption to the major players.

Takeaways

• Bearish Sentiment: The negative commentary from a major pharmaceutical CEO, combined with public criticism from figures like Mark Cuban, suggests significant regulatory and business model risk for the major PBMs.
• Potential Headwinds: Investors in major PBMs (which are often part of larger healthcare companies like CVS Health, Cigna, and UnitedHealth Group) should be aware of the growing pressure for reform in this part of the healthcare industry, which could impact their profitability.